RenovoRx, Inc. (RNXT) stock
RNXTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30124% above fair value
$1.04−0.12 (-10.34%)
Close on Nov 13, 2026Market cap $46.93MP/E –Yield –
RenovoRx price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
RenovoRx's price to book ratio was 6.1× on Nov 11, 2026, against 4.2× a year earlier. Over the last 5 years it ranged from 1.0× to 14.6×, with a median of 4.3×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 6.1× | +2.3 |
| 2025 | Dec 31, 2025 | 3.8× | −0.6 |
| 2024 | Dec 31, 2024 | 4.4× | −5.9 |
| 2023 | Oct 31, 2023 | 10.3× | +7.6 |
| 2022 | Dec 30, 2022 | 2.6× | +0.2 |
| 2021 | Dec 31, 2021 | 2.5× | – |
See a number that looks wrong?